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ABSTRACT
The epidemiological and antifungal susceptibility data for 94 episodes of candidaemia in an Italian
tertiary-care hospital between January 2000 and August 2003 were evaluated by prospective laboratory-
based surveillance. The incidence of fungaemia was 0.90 episodes ⁄ 10 000 patient-days, and the most
common species isolated were Candida albicans (40.4%), Candida parapsilosis (22.3%), Candida tropicalis
(16.0%) and Candida glabrata (12.8%). Among 24 patients who received antifungal prophylaxis, non-
albicans Candida spp. were more prevalent than C. albicans (p 0.012). The 30-day mortality rate was high
(38.2%), particularly for haematological (71.4%) and solid-organ transplant patients (50.0%), and in
individuals with C. tropicalis and C. glabrata bloodstream infections (60.0% and 50.0%, respectively).
In-vitro susceptibility tests demonstrated that 95% of the isolates were susceptible to amphotericin B
(MIC < 2 mg ⁄L), 98.1% to posaconazole (MIC < 1 mg ⁄L), 95.8% to ﬂucytosine (MIC < 32 mg ⁄L) and
ﬂuconazole (MIC < 64 mg ⁄L), and 94.7% to itraconazole (MIC < 1 mg ⁄L). Posaconazole was active
(MIC 0.5 mg ⁄L) against all three isolates of Candida krusei, which had reduced susceptibility to both
ﬂuconazole and itraconazole. Overall, non-albicans Candida spp. accounted for 60% of the episodes of
candidaemia, which could be related to the use of antifungal prophylaxis. Resistance is still uncommon
in Candida spp. recovered from blood cultures. The in-vitro activity of posaconazole is encouraging, and
this agent could play an important role in the management of invasive candidiasis, including episodes
caused by inherently less susceptible species such as C. krusei.
Keywords Amphotericin B, antifungal susceptibility, bloodstream infections, Candida spp., posaconazole, sus-
ceptibility
Original Submission: 23 September 2004; Revised Submission: 13 May 2005; Accepted: 29 June 2005
Clin Microbiol Infect 2006; 12: 75–80
INTRODUCTION
During the past two decades, the frequency of
invasive fungal infections has increased dramat-
ically in hospitalised patients throughout the
world, and Candida has now emerged as one of
the leading causes of bloodstream infections
(BSIs) [1,2]. Data from North American and
European surveillance programmes of hospital-
acquired bacteraemia have revealed that isolates
of Candida spp. are the fourth most common cause
[3,4], accounting for 8–10% of nosocomial BSIs
[1]. Risk-factors for invasive candidiasis include
improvements in intensive care strategies (i.e.,
central venous catheters, mechanical ventilation,
hyper-alimentation), prolonged stays in intensive
care units (ICUs), the development of more
aggressive surgical techniques, and the prolonga-
tion of survival of critically-ill patients [5]. Two
other important factors, observed mainly in can-
cer patients, are colonisation of mucous mem-
branes by yeasts, and neutropenia, resulting from
increased use of antibiotics and anti-neoplastic
agents, respectively [6].
The crude mortality rate of candidaemia is high
(38–75%) [3,4,7], and the attributable mortality
has been estimated at 25–38% [8,9]. During the
past 15 years, the prevalence of infections caused
by non-albicans Candida spp. has increased
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exponentially, so that these organisms now
account for > 50% of episodes of fungaemia in
various surveys. The widespread use of azoles
has been suggested as the main factor responsible
for this changing epidemiology [10–15].
Candida albicans is generally susceptible to all
the antifungal agents available currently. Among
the non-albicans Candida spp., Candida tropicalis
and Candida parapsilosis are both generally sus-
ceptible to azoles, but C. tropicalis is less suscept-
ible to ﬂuconazole than is C. albicans. Candida
glabrata is intrinsically more resistant to antifun-
gal agents, particularly to ﬂuconazole. Candida
krusei is intrinsically resistant to ﬂuconazole, and
infections caused by this species are associated
strongly with previous ﬂuconazole prophylaxis
and neutropenia. Candida lusitaniae, accounting
for 1–2% of candidaemias, is susceptible to
azoles, but has higher intrinsic resistance to
amphotericin B [16]. The increase in invasive
fungal infections, the associated high mortality
rate, and the emergence of antifungal resistance,
have all driven the search for more potent
antifungal drugs. Posaconazole is a novel anti-
fungal triazole, with potent activity against the
yeasts and ﬁlamentous fungi that cause systemic
infections [17–19].
The aims of the present study were to investi-
gate the epidemiology of candidaemia and to
determine the antifungal susceptibility patterns of




Prospective surveillance of nosocomial candidaemia was
conducted at the University Hospital of Modena, Italy,
between January 2000 and August 2003. The hospital has 990
beds, with two adult ICUs, one neonatal ICU, 28 medical
wards and 11 surgical wards, including two centres for solid-
organ transplantations (kidney and liver ⁄multivisceral trans-
plants). Surveillance was based on data from the microbiology
laboratory. Episodes of candidaemia were deﬁned by at least
two positive blood cultures yielding Candida spp. during a
single hospitalisation period. Demographic data, reasons for
hospitalisation, antifungal prophylaxis and outcome were
collected from medical records.
Organism identiﬁcation
Blood specimens were processed by an automated blood
culture system (BACTEC 9240; Becton Dickinson, Sparks, MD,
USA), and viable yeasts were subcultured on Sabouraud
dextrose agar (Labobasi, Vallauris, France). Species identiﬁca-
tion was based on germ tube production, distinctive colour,
and morphology on Candida ID2 Agar (bioMe´rieux, Marcy
l’Etoile, France), together with sugar assimilation proﬁles
obtained using the API ID 32C System (bioMe´rieux). All
isolates were stored at ) 80C in glycerol 10% v ⁄v.
Susceptibility testing
The antifungal agents tested were ﬂuconazole (Pﬁzer Inc.,
New York, NY, USA), posaconazole (Schering-Plough
Research Institute, Kenilworth, NJ, USA), itraconazole (Janssen
Research Foundation, Beerse, Belgium), and amphotericin B
and ﬂucytosine (Sigma Chemical, Milano, Italy). MICs were
determined according to NCCLS guidelines [20]. Final con-
centrations ranged from 0.007 to 4 mg ⁄L for itraconazole and
posaconazole, 0.125–64 mg ⁄L for ﬂuconazole and ﬂucytosine,
and 0.03–16 mg ⁄L for amphotericin B. MICs were read
visually; for posaconazole, itraconazole, ﬂuconazole and ﬂuc-
ytosine, the MIC was the lowest drug concentration that
resulted in an obvious inhibition of growth (c. 50%) compared
with that of the growth control; for amphotericin B, the MIC
was the concentration in the ﬁrst well that was optically clear.
C. krusei ATCC 6258 and C. albicans ATCC 90029 were used as
control strains in all tests. The interpretative breakpoints for
ﬂuconazole, itraconazole and ﬂucytosine were those suggested
previously [20,21]. Since in-vitro susceptibility breakpoints for
amphotericin B and posaconazole have not yet been estab-
lished, susceptible breakpoints of < 2 mg ⁄L for amphotericin B
and <1 mg ⁄L for posaconazole were used, based on pharma-
cokinetic data [22].
Statistical analyses
The chi-square test was used to evaluate the differences in
prevalence between C. albicans and non-albicans Candida spp. in
relation to antifungal prophylaxis and the underlying diseases
of patients, to evaluate the 30-day outcome of patients in
relation to different wards of admission, causes of hospitali-
sation and the species of Candida responsible for the fungae-
mia, and to evaluate the correlation between in-vitro suscep-
tibility to ﬂuconazole, itraconazole and posaconazole and the
use of azole prophylaxis. To investigate the degree of cross-
resistance between azoles, the correlation coefﬁcients between
the MICs of ﬂuconazole, itraconazole and posaconazole were
determined by the Spearman rho non-parametric method.
p < 0.05 was considered signiﬁcant for both analyses.
RESULTS AND DISCUSSION
In total, 94 isolates of Candida spp. were collected
from blood cultures taken from 86 hospitalised
patients. In eight (9.3%) patients, there was
simultaneous or subsequent isolation of two
different Candida spp. Forty-eight (56%) patients
were male, and the median age was 61 years
(range 0–89 years). The overall incidence of can-
didaemia was 0.90 episodes ⁄ 10 000 patient-days.
The most common species isolated was C. albicans
(38 episodes, 40.4%), followed by C. parapsilosis
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(21 episodes, 22.3%), C. tropicalis (15 episodes,
16.0%), C. glabrata (12 episodes, 12.8%), C. krusei
(three episodes, 3.2%), C. lusitaniae (two episodes,
2.1%), Candida guilliermondii (two episodes, 2.1%)
and Candida pelliculosa (one episode, 1.1%).
The reasons for hospitalisation are shown in
Table 1. Overall, 36% of patients with candidae-
mia were from medical wards, 35% from surgical
wards and 29% from ICUs. No signiﬁcant differ-
ences were observed with respect to the preval-
ence of C. albicans and non-albicans Candida spp.
between the different wards and the reasons for
admission. However, for the nine patients with
neutropenia (deﬁned as < 500 neutrophils ⁄mm3),
all the episodes were caused by non-albicans
Candida spp. (p < 0.001; three C. tropicalis, two
C. glabrata, two C. krusei, one C. guilliermondii, one
C. lusitaniae).
The overall incidence of candidaemia observed
in the hospital was in agreement with the results of
another Italian study (1.14 episodes ⁄ 10 000 patient
days) [23], but was higher than that observed in a
large European survey (0.44 episodes ⁄ 10 000
patient-days) [24]. In Modena, C. albicans accoun-
ted for only 40.4% of cases and, among the non-
albicans spp., C. parapsilosis and C. tropicalis were
most prevalent. C. albicans accounted for > 50% of
BSIs and C. tropicalis for only 7% of the episodes in
these two surveys. A possible explanation for
these differences could be the absence of haema-
tological and neutropenic patients, who are at
higher risk of C. tropicalis BSI [25,26], in the study
of Luzzati et al. [23], while a larger sample size
could account for the different species distribution
described by Tortorano et al. [24].
Before diagnosis, 24 patients had received
antifungal prophylaxis: 14 received ﬂuconazole,
four itraconazole, and six nystatin. In this subset
of patients, non-albicans and non-parapsilosis
Candida spp. were signiﬁcantly more prevalent
(p 0.002; Table 2). These data agree with previous
reports describing the increasing rate of colonisa-
tion and infection caused by natively resistant
Candida spp. (C. glabrata and C. krusei) in patients
receiving azoles as prophylaxis [10,15].
Overall, the crude mortality rate at 1 month
after the diagnosis of fungaemia was 38.2%, in
agreement with previous results [6,23,24]. No
signiﬁcant differences in the 30-day mortality rate
were observed with respect to the ward at the
onset of candidaemia, or the reasons for hospital-
isation and neutropenia (data not shown). Haem-
atological (71.4%) and solid-organ transplant
(50.0%) patients showed the highest 30-day mor-
tality rate. Table 3 compares the 30-day mortality
rate of patients with C. albicans (21.1%) and non-
albicans Candida infections (42.8%; p 0.012).
Patients with C. parapsilosis infections had a
poorer outcome than those with C. albicans fung-
aemia (mortality rate, 33.3% vs. 21.1%), but
this difference was not statistically signiﬁcant.
C. tropicalis and C. glabrata were associated with a
poorer outcome (mortality rates of 60.0% and
50.0%, respectively), but only C. tropicalis infec-
tion correlated signiﬁcantly with a worse prog-
nosis than C. albicans (p 0.006). These ﬁndings are
consistent with those described by Viscoli et al. [6]
in cancer patients.
The antifungal susceptibility patterns of the
Candida isolates are summarised in Table 4. The
Table 1. Underlying diseases that caused hospitalisation
of patients suffering from candidaemia
Underlying disease No. (%) of episodes
Solid neoplasia 30 (32.0)
Abdominal surgery 17 (18.1)
Trauma 12 (12.7)
Solid-organ transplantationa 10 (10.6)
Haematological neoplasia 7 (7.4)
Other illnessb 18 (19.2)
aIncludes liver transplantation (nine episodes) and multivisceral transplantation
(one episode).
bIncludes neurological diseases (six episodes), fetal immaturity (six episodes),
respiratory diseases (ﬁve episodes) and AIDS (one episode).




prophylaxis (n = 70)
Antifungal
prophylaxisa (n = 24) p
Candida albicans 34 (48.6%) 4 (16.7%) 0.002
Candida parapsilosis 18 (25.7%) 3 (12.5%)
Candida tropicalis 9 (12.9%) 6 (25.0%)
Candida glabrata 6 (8.6%)b 6 (25.0%)
Others 3 (4.2%) 5 (20.8%)c
aAntifungal agents: nystatin (6), ﬂuconazole (14) and itraconazole (4).
bIncludes Candida krusei (1), Candida guilliermondii (1) and Candida pelliculosa (1).
cIncludes C. krusei (2), Candida lusitaniae (2), and C. guilliermondii (1).
Table 3. Thirty-day mortality rate of patients with fung-
aemia: comparison between episodes caused by Candida
albicans and non-albicans Candida spp.
Candidaemia episodes in 86 patients,
n (mortality rate %)
p
C. albicans vs. non-albicans spp. 38 (21.1) vs. 56 (42.8) 0.029
C. albicans vs. C. parapsilosis 38 (21.1) vs. 21 (33.3) 0.300
C. albicans vs. C. tropicalis 38 (21.1) vs. 15 (60.0) 0.006
C. albicans vs. C. glabrata 38 (21.1) vs. 12 (50.0) 0.052
C. albicans vs. other speciesa 38 (21.1) vs. 8 (25.0) 0.806
aC. krusei (n = 3), C. lusitaniae (n = 2), C. guilliermondii (n = 2), C. pelliculosa (n = 1).
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MICs for the two control strains were within
the expected range (data not shown). Amphoter-
icin B was the most active agent in vitro, with
MIC50 and MIC90 values of 0.25 and 1 mg ⁄L,
respectively. Only one C. lusitaniae isolate, recov-
ered from a patient who had not received anti-
fungal treatment, was resistant to amphotericin B
(MIC 2 mg ⁄L). However, these results may not be
conclusive, since the RPMI 1640 medium may not
be optimal for testing susceptibility to this drug
[27].
The susceptibility of the isolates to ﬂucytosine
was 95.8%. Flucytosine was active against all
C. albicans (MIC90 0.25 mg ⁄L) and C. parapsilosis
(MIC90 0.25 mg ⁄L) isolates. MIC90 values for the
eight less common Candida spp. (including three
isolates of C. krusei) were 16 mg ⁄L. Interestingly,
C. tropicalis was the least susceptible species, with
an MIC90 of > 64 mg ⁄L (three (20%) of 15 isolates
resistant). Although a low percentage (8.0%) of
resistance to ﬂucytosine has been reported among
C. tropicalis isolates [28], a resistance rate of 30.0%
has also been reported [29]. The MIC90 for
C. glabrata was 0.25 mg ⁄L; only one of the 12
C. glabrata isolates was resistant to ﬂucytosine
(MIC > 64 mg ⁄L; resistance rate 8.3%). None of
the patients had received ﬂucytosine before the
diagnosis of candidaemia.
Among the azoles, posaconazole was the most
potent agent in vitro (MIC90 0.25 mg ⁄L), followed
by itraconazole (MIC90 0.5 mg ⁄L) and ﬂuconazole
(MIC90 8 mg ⁄L). Overall, the frequency of resist-
ance to ﬂuconazole was as low (4.2%) as the dose-
dependent susceptibility (5.3%). All C. albicans
and C. parapsilosis isolates were susceptible to
ﬂuconazole (MIC90 1 mg ⁄L). The rates of ﬂucon-
azole resistance among C. glabrata (one (8.3%) of
12) and C. tropicalis (one (6.6%) of 15) were
consistent with those found in other surveillance
studies [30]. Fluconazole was active against only
six of the eight less common Candida spp.; two of
the three C. krusei isolates in this subgroup had
ﬂuconazole MICs of 64 mg ⁄L. In three of the four
episodes of candidaemia caused by ﬂuconazole-
resistant Candida spp. (one C. glabrata and two
C. krusei), the patients had received ﬂuconazole
prophylaxis before diagnosis.
The dose-dependent susceptibility to itracon-
azole was high (37.2%), particularly for C. glabrata
(75%) and C. tropicalis (66.6%). However, the
resistance proﬁle for itraconazole (5.3%) was
similar to that for ﬂuconazole. The ﬁve itracona-
zole-resistant isolates comprised one C. glabrata
(MIC 4 mg ⁄L), one C. tropicalis (MIC > 4 mg ⁄L)
and three C. krusei isolates (MIC 1 mg ⁄L). In two
cases (one C. krusei and one C. tropicalis), the
patients had not received any prophylaxis, while
the other three patients had received ﬂuconazole
before the diagnosis of fungaemia, suggesting the
possible emergence of cross-resistance between
the two azoles [29].
Posaconazole was two-fold more active than
itraconazole against all the species of Candida
tested; the MIC90 values for C. albicans, C. para-
psilosis, C. tropicalis, C. glabrata and the rarer
Candida spp. were 0.125, 0.125, 0.25, 0.25 and
0.5 mg ⁄L, respectively. Furthermore, posaconaz-
ole was active (MIC 0.5 mg ⁄L) against the three
isolates of C. krusei, all of which exhibited reduced
susceptibility to both ﬂuconazole and itraconaz-
ole. One isolate each of C. glabrata and C. tropicalis,
both resistant to ﬂuconazole and itraconazole,
were resistant to posaconazole (MIC 2 and
Table 4. In-vitro activities of ﬁve antifungal agents against













Amphotericin B 0.03–1 0.25 0.5 0 (0) –
Flucytosine 0.125–16 0.125 0.25 0 (0) 1 (2.6)
Fluconazole 0.125–32 0.25 1 0 (0) 2 (5.2)
Itraconazole 0.006–0.5 0.06 0.25 0 (0) 4 (10.5)
Posaconazole 0.006–0.25 0.03 0.125 0 (0) –
C. parapsilosis
(21)
Amphotericin B 0.25–1 0.25 0.5 0 (0) –
Flucytosine 0.125–0.5 0.125 0.25 0 (0) 0 (0)
Fluconazole 0.125–32 0.5 1 0 (0) 1 (4.7)
Itraconazole 0.06–0.5 0.125 0.25 0 (0) 8 (38.0)
Posaconazole 0.03–0.5 0.06 0.125 0 (0) –
C. tropicalis
(15)
Amphotericin B 0.25–1 0.5 1 0 (0) –
Flucytosine 0.125 to > 64 0.125 > 64 3 (20) 0 (0)
Fluconazole 0.25 to > 64 0.5 8 1 (6.6) 0 (0)
Itraconazole 0.125 to > 4 0.25 0.5 1 (6.6) 10 (66.6)
Posaconazole 0.03 to > 4 0.125 0.25 1 (6.6) –
C. glabrata
(12)
Amphotericin B 0.25–1 0.25 0.5 0 –
Flucytosine 0.125 to > 64 0.125 0.25 1 (8.3) 0 (0)
Fluconazole 0.125–64 4 8 1 (8.3) 0 (0)
Itraconazole 0.125–4 0.5 0.5 1 (8.3) 9 (75.0)
Posaconazole 0.03–2 0.25 0.25 1 (8.3) –
Other species
(8)b
Amphotericin B 0.25–2 0.25 2 1 (12.5) –
Flucytosine 0.125–16 0.25 16 0 2 (25.0)
Fluconazole 0.5–64 4 64 2 (25) 2 (25.0)
Itraconazole 0.125–1 0.5 1 3 (37.5) 4 (50.0)
Posaconazole 0.06–0.5 0.125 0.5 0 –
All
organisms (94)
Amphotericin B 0.03–2 0.25 1 1 (1.0) –
Flucytosine 0.125 to > 64 0.125 0.5 4 (4.2) 3 (31.9)
Fluconazole 0.125 to > 64 0.5 8 4 (4.2) 5 (5.3)
Itraconazole 0.006 to > 4 0.125 0.5 5 (5.3) 35 (37.2)
Posaconazole 0.006 to > 4 0.06 0.25 2 (2.1) –
R, resistant; S-DD, susceptible–dose dependent; S, susceptible.
aSusceptibility breakpoints (mg ⁄L): amphotericin B ‡ 2 (R); ﬂuconazole £ 8 (S),
16–32 (S-DD), ‡ 64 (R); itraconazole £ 0.125 (S), 0.25–0.5 (S-DD), ‡ 1 (R);
posaconazole ‡ 1 (R); ﬂucytosine £ 8 (S), 16–32 (S-DD), ‡ 64 (R).
bC. krusei (n = 3), C. lusitaniae (n = 2), C. guilliermondii (n = 2), C. pelliculosa (n = 1).
The resistant isolates were: one C. lusitaniae (resistant to amphotericin B), one
C. krusei (resistant to itraconazole) and two C. krusei (resistant to itraconazole and
ﬂuconazole).
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> 4 mg ⁄L, respectively). It is of note that the
C. glabrata isolate was recovered from a patient
who had received ﬂuconazole prophylaxis; thus,
it is possible that it had acquired resistance to
ﬂuconazole, and had become cross-resistant to
posaconazole [29]. For the C. tropicalis isolate, the
most likely explanation is rare primary resistance
to all three azoles.
Table 5 shows the relationship between in-vitro
antifungal susceptibility and exposure to azole
prophylaxis. Candida spp. isolated from patients
who had received azoles before the onset of
fungaemia were signiﬁcantly less susceptible
to ﬂuconazole, itraconazole and posaconazole
(p 0.006, p 0.013 and p 0.026, respectively). These
ﬁndings suggest that azole prophylaxis could be
responsible for the emergence of cross-resistance
between ﬂuconazole, itraconazole and posacon-
azole, or that it could account for the selection of
Candida spp. that are less susceptible to azoles. No
signiﬁcant correlations were observed between
the MICs of ﬂuconazole, itraconazole and posac-
onazole (data not shown).
In conclusion, the incidence of candidaemia at
this institution was consistent with the data
obtained from other studies in the USA and
Europe [31,32,33]. C. albicans remains the most
prevalent species, but non-albicans Candida spp.
accounted for 60% of episodes. One factor that
may contribute to the emergence of non-albicans
Candida spp. is the use of antifungal prophylaxis
[10–15]. The relatively high proportion of
C. parapsilosis isolates, typically related to the use
of central venous catheters and parenteral nutri-
tion [32–34], raises the possibility of inadequate
infection control practices. The severity of Candida
BSI was conﬁrmed by the 30-day mortality rate of
38.2%. Although signiﬁcant differences were not
observed when considering the causes of hospi-
talisation, haematological and solid-organ trans-
plant patients had poorer outcomes. C. tropicalis
and C. glabrata were related to the highest mortal-
ity rates. None of the C. albicans and C. parapsilosis
isolates exhibited resistance to azoles; these data
suggest that azole resistance is not frequent in BSI
caused by these Candida species. Finally, the data
obtained for posaconazole are encouraging, and
suggest that this new agent may play an important
role in the management of invasive candidiasis,
including infections caused by inherently less
susceptible species such as C. krusei.
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